skip to content
Primary navigation


Drug - Zelepar (selegiline) rapidly disintegrating tablets 1.25 mg

October 2007

Description An irreversible MOA-B inhibitor intended for oral mucosal absorption
Dose 1.25 mg QD x 6 weeks, then 2.5 mg QD
AWP $4.67/tab

Zelepar criteria

  • Patient has Parkinson’s disease AND
  • Patient is on levodopa/carbidopa and is experiencing significant “off” periods or a deterioration in the quality of their response to therapy AND
  • Patient has tried a 5mg dose of oral selegiline tablets or capsules but has had therapeutic failure due to adverse events


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top